Prostate cancer drug under the microscope: who gets it and how well does it work?
NCT ID NCT07450157
First seen Mar 22, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study analyzed medical records of over 6,400 prostate cancer patients to see who received a new treatment called 177Lu-PSMA-617 and how they fared. Researchers looked at patient traits, treatment patterns, and survival rates. The goal was to understand early real-world use of this drug, not to test its effectiveness directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.